Articles

How investors can take advantage of a quirky midterm election cycle

Stocks tend to struggle during midterm election years — but 2026 could be a buying opportunity.

When retirees go back to work is it a sign of a strong labor force — or a recession?

What “unretirements” can tell us about the job market

The stock market right now is poised for a breakout — or a breakup

Bears fumble control of the tape, but the S&P 500 is still range-bound.

Bonds are having their best year since 2020. But don’t expect the same returns next year.

An uncertain outlook for inflation and interest rates could drive yields higher next year, weighing on bond prices.

Nvidia and other chip stocks rise — but the AI trade may not be back for good

Micron’s outlook was lifting AI stocks across the board on Thursday, but a more sustained catalyst may not arrive until next year.

Uber’s stock is almost historically cheap. Are robotaxis an existential threat?

Bernstein analysts said Uber investors have been overly fearful of the threat posed by self-driving cars, particularly if autonomous-vehicle technology gets widely licensed.

OK, boomer: Why you should start giving your money to your adult kids now

There’s no point in waiting until you die — especially in this economy. How to know how much you can part with.

CoreWeave and Nebius shares rebound. Were debt fears too extreme?

Micron’s earnings report is lifting AI stocks in general, but a Seaport analyst wondered if investors were reacting too severely to debt concerns.

Micron just had its Nvidia moment. What comes next for the stock?

Micron’s dramatic beat has analysts feeling upbeat about the company’s ability to be a huge beneficiary of the AI boom.

Marijuana stocks jump, as Trump set to sign executive order that would reclassify the drug

Tilray and Canopy Growth shares were among big gainers Thursday.

A new generation of weight-loss drugs is getting closer to patients. Here’s how they differ from Wegovy and Zepbound.

Eli Lilly and Novo Nordisk file their new weight-loss drugs with the FDA.

Deutsche Bank survey reveals what troubles investors most in 2026 – and what doesn’t

Curiously, those events which have shaken markets most severely in recent years are low down the list of priorities for 2026 in investor mindsets.
1 17 18 19 20 21 2,511